27. Kantarjian HM, Shah NP, Cortes JE et al (2011) Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). *Blood* 119(5):1123–1129
28. Larson RA, Hochhaus A, Hughes TP et al (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. *Leukemia* 26:2197–2203
29. le Coutre PD, Giles FJ, Hochhaus A et al (2012) Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. *Leukemia* 26:1189–1194
30. Mahon FX, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. *Lancet Oncol* 11:1029–1035
31. Milojkovic D, Nicholson E, Apperley JF et al (2010) Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. *Haematologica* 95:224–231
32. Müller MC, Cortes JE, Kim DW et al (2009) Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations. *Blood* 114:4944–4953
33. Müller MC, Cross NC, Erben P et al (2009) Harmonization of molecular monitoring of CML therapy in Europe. *Leukemia* 23:1957–1963
34. Nicolini FE, Basak GW, Soverini S et al (2011) Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. *Blood* 118:5697–5700
35. O'Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 348:994–1004
36. Preudhomme C, Guilhot J, Nicolini FE et al (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. *N Engl J Med* 363:2511–2521
37. Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukaemia (CML). *Best Pract Res Clin Haematol* 22:295–302
38. Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. *N Engl J Med* 362:2251–2259
39. Saussele S, Lauseker M, Gratwohl A et al (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. *Blood* 115:1880–1885
40. Simonsson B, Gedde-Dahl T, Markevarn B et al (2011) Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. *Blood* 118:3228–3235
41. Soverini S, Hochhaus A, Nicolini FE et al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. *Blood* 118:1208–1215
42. Weisberg E, Manley PW, Cowan-Jacob SW et al (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. *Nat Rev Cancer* 7:345–356

Onkologie 2012 · 18:1114
 DOI 10.1007/s00761-012-2376-x
 Online publiziert: 1. Dezember 2012
 © Springer-Verlag Berlin Heidelberg 2012

R. Knüchel-Clarke¹ · A. Hartmann²

¹ Institut für Pathologie, Universitätsklinikum Aachen

² Universitätsklinikum Erlangen

Erratum zu: Pathogenese und Tumorklassifikation des Harnblasenkarzinoms

Onkologie 18:961–970

<http://dx.doi.org/10.1007/s00761-012-2334-7>

In dem Beitrag wurde Abbildung 2 mit Abbildung 3 vertauscht. Wir bitten, den Fehler zu entschuldigen.

Korrespondenzadresse

Prof. Dr. R. Knüchel-Clarke
 Institut für Pathologie,
 Universitätsklinikum Aachen
 Pauwelsstraße 30, 52074 Aachen
rkneuchel-clarke@ukaachen.de